Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell linesHartmans, E., Linssen, M. D., Sikkens, C., Levens, A., Witjes, M. J. H., van Dam, G. M. & Nagengast, W. B., 13-Mar-2017, In : Oncotarget. 8, 18, p. 29846-29856 11 p.
Research output: Contribution to journal › Article › Academic › peer-review
Esophageal carcinoma (EC) is a global health problem, with disappointing 5-year survival rates of only 15-25%. Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced receptor upregulation its future clinical application may be optimized.
|Number of pages||11|
|Publication status||Published - 13-Mar-2017|
- targeted photodynamic therapy, esophageal cancer, epidermal growth factor receptor family (HER-family), targeted treatment, TRASTUZUMAB-BASED PHOTOIMMUNOTHERAPY, HIGH-GRADE DYSPLASIA, BARRETTS-ESOPHAGUS, MONOCLONAL-ANTIBODIES, BREAST-CANCER, TUMORS, EGFR, HER2, EXPRESSION, TRANSDUCTION